Unicycive Therapeutics (UNCY) Operating Leases (2021 - 2026)

Unicycive Therapeutics' (UNCY) quarterly Operating Leases came in at $217000.0 in Q1 2026, up 85.47% on a QoQ basis from $117000.0 in Q4 2024.

Unicycive Therapeutics (UNCY) Operating Leases (2021 - 2026) Analysis & Trends

Unicycive Therapeutics (UNCY) has 5 years of Operating Leases data on file, last reported at $217000.0 in Q1 2026.

Quarterly Operating Leases changed N/A year-over-year to $217000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $217000.0 (changed N/A YoY) and the FY2024 annual result came in at $117000.0, down 74.89% from the prior year.
Operating Leases climbed to $217000.0 in Q1 2026, from $117000.0 in the prior quarter.
In the past five years, Operating Leases ranged from a high of $800000.0 in Q4 2022 to a low of $29000.0 in Q3 2022.
A 4-year average of $355923.1 and a median of $274000.0 in 2024 frame the typical range for Operating Leases.
Annual changes were most pronounced in 2023 — Operating Leases jumped 1803.45% — and 2024, when it plunged 74.89%.
Tracing UNCY's Operating Leases over 4 years: stood at $800000.0 in 2022, then sank by 41.75% to $466000.0 in 2023, then sank by 74.89% to $117000.0 in 2024, then surged by 85.47% to $217000.0 in 2026.
The last three Operating Leases figures came in at $217000.0 (Q1 2026), $117000.0 (Q4 2024), and $265000.0 (Q3 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Unicycive Therapeutics	151.01 Mn	151.01 Mn	-

Download Data